Photodynamic therapy composition
US11975074B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 15, 2020 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Aug 26, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K49/0056
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.